| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 21 Feb 2025 | 24 Feb 2025 |
| Disclosure under Regulation 30 | ||
| Board Meeting | 14 Feb 2025 | 5 Feb 2025 |
| Quarterly Results Healthcare Global Enterprises Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 ,inter alia, to consider and approve and take on record the Unaudited Financial Results (both Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2024 The Board Meeting to be held on 13/02/2025 has been revised to 14/02/2025 The Board Meeting of the Company would commence on Thursday, February 13, 2025 and would continue on Friday, February 14, 2025, and that the Unaudited Financial Results of the Company shall be discussed and considered by the Board on February 14, 2025. (As per BSE Announcement Dated on 11/02/2025) Considered and approved the unaudited financial results of the Company for the quarter and nine months ended Deceber 31, 2024. (As Per BSE Announcement Dated on 14.02.2025) | ||
| Board Meeting | 7 Feb 2025 | 7 Feb 2025 |
| Changes in directorship of HealthCare Global Enterprises Limited (the Company) | ||
| Board Meeting | 9 Nov 2024 | 24 Oct 2024 |
| Healthcare Global Enterprises Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2024 inter alia to consider and approve and take on record the unaudited financial results for the quarter and six months ended Sept 30 2024. Results-Financial Results for September 30, 2024 (As Per BSE Announcement Dated on: 09/11/2024) | ||
| Board Meeting | 8 Aug 2024 | 25 Jul 2024 |
| Healthcare Global Enterprises Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve and take on record the Unaudited Financial Results (both Standalone and Consolidated) of the Company for the quarter ended June 30 2024 (Unaudited Financial Results). Unuaudited Financial Results of the Company for the quarter ended June 30, 2024 (As Per BSE Announcement dated on 08.08.2024) | ||
| Board Meeting | 29 May 2024 | 15 May 2024 |
| Healthcare Global Enterprises Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 inter alia to consider and approve Audited financial results for the year ended March 31 2024 Board of Directors of the Company (Board), at their meeting held on this day, May 29, 2024, inter alia, has considered and approved the following agenda: 1. Audited Financial Results (Standalone and Consolidated) of the Company for the year ended March 31, 2024, together with Auditors Report thereon; 2. Issue and allotment of 28,255 (Twenty-Eight Thousand Two Hundred Fifty Five) equity shares of the Company of INR 10 each, upon exercise of Employee Stock Options in accordance with the existing Employee Stock Option Schemes of the Company. 3. Re-appointment of Ms. Geeta Mathur (DIN: 02139552), as an Independent Director of the Company for a term of three (3) years with effect from June 17, 2024, subject to the approval of shareholders of the Company, and that Ms. Geeta Mathur shall not be liable to retire by rotation. The Company shall make detailed disclosure under Regulation 30 of SEBI LODR Regulations, 2015 in this regard. Pursuant to Regulation 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2024, together with Auditors Report, as approved by the Board. The financial results are also being made available on the Companys website at www.hcgoncology.com We hereby declare that the Statutory Auditors of the Company, M/s. B S R & Co. LLP, have issued an Audit Report with an unmodified opinion on Audited Financial Results (Standalone and Consolidated) of the Company for the year ended March 31, 2024. (As Per BSE Announcement Dated on 29.05.2024) | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
